Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 4.42% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
Risky - Negative Operating Profits
Below par performance in long term as well as near term
Stock DNA
Healthcare Services
INR 29 Cr (Micro Cap)
NA (Loss Making)
63
0.00%
-1.48
25.00%
-8.56
Total Returns (Price + Dividend) 
Chennai Meena for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Chennai Meenakshi Multispeciality Hospital Ltd is Rated Strong Sell
Chennai Meenakshi Multispeciality Hospital Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 15 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 October 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
13-Nov-2026 | Source : BSEPursuant to Regulation 30 read with Schedule III of the SEBI (LODR) 2015 we wish to inform you that an order dated November 10 2026 has been passed by the Honble XII Judge Court of Small Causes Chennai in M.P. No 1 of 2026 in RLTOP No. 130 of 2026 filed against the Company by one of the co-owners of the leased premises.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
13-Nov-2026 | Source : BSEPursuant to Reg 39(3) of SEBI (LODR) 2015 we wish to inform that the Company has issued Duplicate Share Certificates to Mr. Inder Chand Kothari L (Folio No : 00008717) for 100 shares.
Results For The Quarter Ended 30Th June 2026
03-Nov-2026 | Source : BSEIt is to inform you that the Board of Directors of the Company at its meeting held on 11th August 2026 which commenced at 11.30am and concluded at 3.15pm inter-alia considered and approved the unaudited Financial Results comprising the statement of profit & loss account for the quarter ended 30th June 2026 along with Limited Review Report submitted by the Statutory Auditors of the Company as required under Regulation 33 of SEBI (LODR) 2015 and also transacted other agenda items as circulated along with notice.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.14%)
Held by 0 FIIs
Jayanthi Radhakrishnan (25.59%)
Mahendra Girdharilal Wadhwani (2.65%)
39.82%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 0.58% vs -12.44% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 0.00% vs 100.00% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 7.73% vs -9.52% in Sep 2024
Growth in half year ended Sep 2025 is 44.34% vs -1,866.67% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 6.16% vs -10.50% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 33.14% vs -8,550.00% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 6.38% vs -8.85% in Mar 2025
YoY Growth in year ended Mar 2026 is 18.25% vs -218.60% in Mar 2025